ABBOTT PARK, Ill., Nov. 6, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from long-term open-label extensions of the PREMIER and DE019 Phase 3 studies, which evaluated HUMIRA® ...
(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...
Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...
WASHINGTON (AP) — Shares of AstraZeneca and its partner Rigel Pharmaceuticals Inc. fell Thursday after the companies reported that their experimental rheumatoid arthritis drug was less effective than ...
DEAR DR. ROACH: I’m a 67-year-old healthy male, but I do take Humira for rheumatoid arthritis (RA). It does a wonderful job for me with no side effects. It does such a good job that I can periodically ...
Johnson & Johnson (NYSE:JNJ) has discontinued a combination therapy involving its experimental antibody therapy, nipocalimab, for rheumatoid arthritis after a failure in a mid-stage trial, which ...
NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...
SAN DIEGO — Erinn Maury knew Remicade wasn’t the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte’s swollen, painful ...
AbbVie has been accused of exploiting the country’s patent system to drive up prices for its rheumatoid arthritis drug Humira and cancer drug Imbruvica by the U.S. House Committee on Oversight and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback